Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 4.

Diermeier, S., Iberl, J., Vetter, K., Haug, M., Reischl, B., Buttgereit, A., Schuermann, S., Spoerrer, M., Goldmann, W. H., Fabry, B., Elhimine, F., Stehle, R., Pfitzer, G., Winter, L., Clemen, C., Schroeder, R. and Friedrich, O. (2015). DesR349P mutation results in ultrastructural disruptions and compromise of skeletal muscle biomechanics already at preclinical stages in young mice before the onset of protein aggregation. Mol. Biol. Cell, 26. BETHESDA: AMER SOC CELL BIOLOGY. ISSN 1939-4586

Stegelmann, F., Griesshammer, M., Koschmieder, S., Reiter, A., Hochhaus, A., Heidel, F., von, Bubnoff N., Kindler, T., Hebart, H., Bangerter, M., Wolleschak, D., Moehle, R., Scheid, C., Reim, R., Sutter, U., Vetter, K., Doehner, H. and Doehner, K. (2017). Pomalidomide plus ruxolitinib in myelofibrosis: Updated results from the MPNSG-0212 trial. Oncol. Res. Treat., 40. S. 149 - 150. BASEL: KARGER. ISSN 2296-5262

Stegelmann, F., Griesshammer, M., Koschmieder, S., Reiter, A., Hochhaus, A., Heidel, F., von Bubnoff, N., Kindler, T., Hebart, H., Bangerter, M., Wolleschak, D., Moehle, R., Scheid, C., Reim, R., Sutter, U., Vetter, K., Doehner, H. and Doehner, K. (2017). COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110). Haematologica, 102. S. 280 - 281. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Stegelmann, F., Hebart, H., Bangerter, M., Wolleschak, D., Griesshammer, M., Koschmieder, S., Hochhaus, A., Heidel, F., Moehle, R., Reiter, A., Scheid, C., von Bubnoff, N., Kirschbaum, R., Reim, R., Sutter, U., Vetter, K., Doehner, H., Schlenk, R. F. and Doehner, K. (2016). Ruxolitinib/Pomalidomide combination therapy in myelofibrosis: Current data from the MPNSG-0212 trial. Oncol. Res. Treat., 39. S. 233 - 235. BASEL: KARGER. ISSN 2296-5262

This list was generated on Thu Dec 2 07:19:00 2021 CET.